Resumen

MENDIVIL A, Carlos Olimpo. Orlistat and Sibutramine in the management of metabolic syndrome. Acta Med Colomb [online]. 2005, vol.30, n.3, pp.168-170. ISSN 0120-2448.

Increased body fat mass is associated with a reduction in insulin sensitivity and the development of a myriad disorders characteristic of the metabolic syndrome. On the other hand, a reduction in the amount of body fat improves those alterations significantly. There are currently two medications approved for the management of excess weight and obesity: Orlistat and sibutramine. The purpose of this paper is to review the main pharmacological and clinical properties of both molecules, emphazising their impact on the components of metabolic syndrome.

Palabras clave : obesity; metabolic syndrome; orlistat; sibutramine.